Product: | Idarubicin hydrochloride | ||||
---|---|---|---|---|---|
Catalog Number: | 17518 | ||||
CAS Number: | 57852-57-0 | ||||
Synonyms: |
DMDR; IMI-30; Idamycin; 4-Demethoxy Daunorubicin; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione |
||||
Pricing: |
|
||||
Formula: | C26H27NO9 HCl | ||||
Molecular Weight: | 533.95 | ||||
Structure: |
![]() |
||||
Appearance: | Solid | ||||
Category: | Anti-cancer compounds | ||||
Stability: | Stable under recommended storage conditions | ||||
Storage: |
Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: 2-8°C |
||||
Transportation: |
IATA: Hazard Class: 6.1; UN Number: UN2811; Packing Group: II; Shipping Name: Toxic solid, organic, n.o.s. ((7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxynaphthacene-5,12-dion) |
||||
Literature References: |
Borchmann, P., et al., Idarubicin: a brief overview on pharmacology and clinical use. Int. J. Clin. Pharmacol. Ther. 35, 80-83, (1997); Guxman, M.L., et al., Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. U. S. A. 99, 16220-16225, (2002); Tokarska-Schlattner, M., et al. , Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol. Pharmacol. 61, 516-523, (2002); Merck 14,4886 |
||||
MSDS: | |||||
Description: |
Idarubicin is an anthracycline antibiotic that is an anti-leukemia agent with higher DNA binding capacity and greater cytotoxicity than daunorubicin |